{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:34:20Z","timestamp":1790642060422,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.ophtha.2012.06.037","type":"journal-article","created":{"date-parts":[[2012,8,17]],"date-time":"2012-08-17T00:45:40Z","timestamp":1345164340000},"page":"2587-2591","source":"Crossref","is-referenced-by-count":99,"title":["Benefit from Bevacizumab for Macular Edema in Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized Study"],"prefix":"10.1016","volume":"119","clinical-trial-number":[{"clinical-trial-number":"nct00906685","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"David L.","family":"Epstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peep V.","family":"Algvere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunvor","family":"von Wendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Seregard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Kvanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2012.06.037_bib1","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/archopht.1996.01100140443012","article-title":"Prevalence and associations of retinal vein occlusion in Australia: the Blue Mountains Eye Study","volume":"114","author":"Mitchell","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2012.06.037_bib2","first-page":"133","article-title":"The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study","volume":"98","author":"Klein","year":"2000","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.ophtha.2012.06.037_bib3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2012.06.037_bib4","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.ophtha.2010.01.060","article-title":"Natural history of central retinal vein occlusion: an evidence-based systematic review","volume":"117","author":"McIntosh","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2012.06.037_bib5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ajo.2011.01.040","article-title":"Levels of VEGF but not VEGF(165b) are increased in the vitreous of patients with retinal vein occlusion","volume":"152","author":"Ehlken","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2012.06.037_bib6","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2012.06.037_bib7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nature03987","article-title":"Pathophysiological consequences of VEGF-induced vascular permeability","volume":"437","author":"Weis","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ophtha.2012.06.037_bib8","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2012.06.037_bib9","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","article-title":"Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2012.06.037_bib10","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.ophtha.2012.01.022","article-title":"Bevacizumab for macular edema in central retinal vein occlusion: a prospective randomized double masked clinical study","volume":"119","author":"Epstein","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2012.06.037_bib11","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2012.06.037_bib12","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.ophtha.2011.12.028","article-title":"Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant","volume":"119","author":"Yeh","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2012.06.037_bib13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00417-011-1860-0","article-title":"Retinal sensitivity after resolution of the macular edema associated with retinal vein occlusion","volume":"250","author":"Ota","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2012.06.037_bib14","first-page":"4048","article-title":"Photoreceptor function in eyes with macular edema","volume":"41","author":"Lardenoye","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2012.06.037_bib15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/archopht.126.4.513","article-title":"The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study","volume":"126","author":"Klein","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2012.06.037_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00417-009-1167-6","article-title":"Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion","volume":"248","author":"Ach","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2012.06.037_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1755-3768.2008.01355.x","article-title":"Bevacizumab as adjuvant for neovascular glaucoma","volume":"88","author":"Beutel","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2012.06.037_bib18","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.ophtha.2008.02.026","article-title":"Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases","volume":"115","author":"Wakabayashi","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2012.06.037_bib19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","article-title":"Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans","volume":"146","author":"Krohne","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2012.06.037_bib20","first-page":"3","article-title":"Lucentis (ranibizumab)","year":"2011"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642012005970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642012005970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T07:00:04Z","timestamp":1542783604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642012005970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0161642012005970"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2012.06.037","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717954853.793461895","asserted-by":"object"}]},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}